PubRank

John H Krege

Author PubWeight™ 30.10‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009 2.16
2 Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006 1.96
3 Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006 1.58
4 Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 2005 1.36
5 Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 2009 1.35
6 Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005 1.34
7 A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 2015 1.23
8 Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2004 1.15
9 Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res 2013 1.14
10 Osteosarcoma and teriparatide? J Bone Miner Res 2007 1.14
11 The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 2005 1.11
12 Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin 2009 1.02
13 Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res 2009 1.00
14 Prognostic utility of a semiquantitative spinal deformity index. Bone 2005 0.99
15 PINP as an aid for monitoring patients treated with teriparatide. Bone 2010 0.98
16 Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006 0.97
17 Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 2010 0.91
18 Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 2007 0.91
19 First fractures among postmenopausal women with osteoporosis. J Bone Miner Metab 2010 0.89
20 Changes in vitamin D metabolites during teriparatide treatment. Bone 2012 0.88
21 Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 2005 0.85
22 Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone 2005 0.84
23 Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Womens Health 2013 0.82
24 Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab 2007 0.81
25 Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 2010 0.81
26 Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia. FASEB J 2010 0.80
27 Long-term raloxifene for postmenopausal osteoporosis. Curr Med Res Opin 2011 0.80
28 Comments on Initial experience with teriparatide in the United States. Curr Med Res Opin 2006 0.77
29 Benefits and risks of raloxifene by vertebral fracture status. Curr Med Res Opin 2010 0.76
30 Teriparatide, osteoporosis, calcium, and vitamin D. N Engl J Med 2005 0.75